FdaApplication
NDA 020895
Identifiers
- fda_app_no: NDA020895
Properties
| Property | Value |
|---|---|
| applicant_name | VIATRIS SPECIALTY LLC |
| application_type | NDA |
| approval_date | 1998-03-27 |
Revenue by product
VIAGRA
| Period | Revenue |
|---|---|
| Q2 2026 | $112.9M |
| Q1 2026 | $95.0M |
| Q4 2025 | $104.2M |
| Q3 2025 | $105.2M |
| Q2 2025 | $100.3M |
| Q1 2025 | $98.5M |
| Q4 2024 | $88.6M |
| Q3 2024 | $100.2M |
| Q2 2024 | $106.1M |
| Q1 2024 | $100.7M |
| Q4 2023 | $92.3M |
| Q3 2023 | $110.5M |
| Q2 2023 | $111.0M |
| Q1 2023 | $115.0M |
| Q4 2022 | $97.0M |
| Q3 2022 | $117.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VIAGRA | SILDENAFIL CITRATE | EQ 50MG BASE | TABLET;ORAL |
| VIAGRA | SILDENAFIL CITRATE | EQ 25MG BASE | TABLET;ORAL |
| VIAGRA | SILDENAFIL CITRATE | EQ 100MG BASE | TABLET;ORAL |
3 products